ISSN: 2161-0460

Zeitschrift für Alzheimer-Krankheit und Parkinsonismus

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Indiziert in
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • Akademische Schlüssel
  • JournalTOCs
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Elektronische Zeitschriftenbibliothek
  • RefSeek
  • Hamdard-Universität
  • EBSCO AZ
  • OCLC – WorldCat
  • SWB Online-Katalog
  • Virtuelle Bibliothek für Biologie (vifabio)
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Euro-Pub
  • ICMJE
Teile diese Seite

Abstrakt

The Mild Cognitive Impairment (MCI) in Searching for its Clinical Identity, Comment of the NEDICES Cohort Data

Félix Bermejo P *

Elderly cognitive decline is a well-known disorder that affects many people. One of the first medical definitions for this clinical reality was Kral’s “benign and malignant senescent forgetfulness”. After Kral, many authors proposed other entities of memory impairment or cognitive decline in the elderly: “Age-associated memory impairment”, “Agerelated memory decline”, “Ageing-associated cognitive decline”, Mild Cognitive Impairment (MCI) and “Cognitive Impairment Non-Dementia” (CIND) of the Canadian Study. And very recently, the DSM-V defined the elderly cognitive decline as a “Minor Neurocognitive Disorder”. By large, MCI had far more citations than any other predementia state in MEDLINE (more than 8,000 reviews in this medical database). This success in the medical literature is rather the expression of a controversy than a well-defined clinical disorder. In fact, its medical birth, near 30 years ago, was as a research entity that precludes dementia. The theoretical definition of MCI is quite clear (A cognitive decline with an increased dementia risk); the problem is the operational definition of this cognitive decline in many elderly that have produced, along the time many definitions and subtypes. In summary, MCI is defined as cognitive decline (of one or more cognitive domains, mainly memory) with normal or near normal functional activities of the patient, and obviously, no dementia. According to the type and extension of the affected cognitive domain, MCI has received several subtyping: Amnestic- only memory affected, non-amnestic- deficit in another cognitive domain different from the memory, such as executive capacities. Both of them could be shown alone or in combination (only amnestic MCI, only non-amnestic, or amnestic o non-amnestic plus other cognitive domain affected. There are several well-known characteristics of this entity. First, it is prevalent in the elderly, more prevalent (about 10-15%) that the dementia states (5-10%). Obviously, in both conditions, its prevalence oscillates with the operational definitions used and with the population demographic characteristics studied: age, sex and education. Second, MCI involves an increased risk of dementia and mortality in relation to the normal cognition elders. Third, it is an unstable disorder, many MCI cases do not evolve to dementia, and many others change to normal cognition in a period of 2-3 years. Fourth, MCI is a heterogeneous entity with many risk factors and aetiologies; it is not always the predementia state of the main neurodegenerative disorders of the elderly: Alzheimer disease (AD), Parkinson disease (PD) and others; cerebral vascular diseases, depression and elderly co-morbidities underpinning many MCI cases. From an epidemiological point of view, it is interesting to comment the MCI definition in three different scenarios: the clinical setting, the population-based surveys, and the trial studies because in these three scenarios, MCI had different characteristics and evolution.

Haftungsausschluss: Dieser Abstract wurde mit Hilfe von Künstlicher Intelligenz übersetzt und wurde noch nicht überprüft oder verifiziert.